Home
Company
Our Vision
Our Leadership Team
Naronapride (ATI-7505)
About Naronapride (ATI-7505)
Mechanism of Action
Development Status
Chemistry and Manufacturing
Latest Regulatory Developments
Knowledge Centre
Chronic Idiopathic Constipation
Irritable Bowel Syndrome
GERD
Functional Dyspepsia
Gastroparesis
News
Press
>
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
Contact
Press
5th October, 2021
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
Download.pdf
Home
Company
Our Vision
Our Leadership Team
Naronapride (ATI-7505)
About Naronapride (ATI-7505)
Mechanism of Action
Development Status
Chemistry and Manufacturing
Latest Regulatory Developments
Knowledge Centre
Chronic Idiopathic Constipation
Irritable Bowel Syndrome
GERD
Functional Dyspepsia
Gastroparesis
News
Press
>
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
Contact
